AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Duke covid spike9/18/2023 ![]() ![]() SARS-CoV-2, the etiological agent of COVID-19, has spread worldwide, resulting in a global health and economic crisis that mass vaccinations are trying to resolve. ![]() Hence, both humoral and cellular spike–specific immunity should be tested after vaccination to define the correlates of protection necessary to evaluate current vaccine strategies. The magnitude of these spike-specific T cell responses cannot be predicted from the neutralizing antibody levels. However, a wide heterogeneity of the magnitude of spike-specific T cell responses characterized the individual responses, irrespective of the time of analysis. Using this test, we observed a similar mean magnitude of T cell responses between the vaccinees and SARS-CoV-2 convalescents 3 months after vaccination or virus priming. The sensitivity of this rapid test is comparable to that of traditional methods of T cell analysis (ELISPOT, activation-induced marker). We tested the sensitivity and performance of a simple and rapid SARS-CoV-2 spike protein–specific T cell test based on the stimulation of whole blood with peptides covering the SARS-CoV-2 spike protein, followed by cytokine (IFN-γ, IL-2) measurement in different cohorts including BNT162b2-vaccinated individuals ( n = 112), convalescent asymptomatic and symptomatic COVID-19 patients ( n = 130), and SARS-CoV-1–convalescent individuals ( n = 12). Defining the correlates of protection necessary to manage the COVID-19 pandemic requires the analysis of both antibody and T cell parameters, but the complexity of traditional tests limits virus-specific T cell measurements. ![]()
0 Comments
Read More
Leave a Reply. |